title: Drug resistance among TB cases and its clinical implications.
abstract: The emergence of M. tuberculosis strains resistant to at least, Isoniazid (INH) and Rifampicin (RIF), the two most potent drugs of first-line anti-TB therapy is termed multidrug drug-resistant TB (MDR-TB). This is a cause of concern to TB Control Programmes worldwide. When MDR-TB strains become resistant to the major second-line drugs, one of the fluouroquinolones and one of the three injectable drugs (Amikacin, Kanamycin and Capreomycin), it is defined as extensively drug resistant TB.(1,2) MDR-TB is a manmade, costly and deadly problem. Rapid diagnosis of MDR-TB is essential for the prompt initiation of effective second-line therapy to improve treatment outcome and limit transmission of the disease.
authors.affiliation: New Delhi Tuberculosis Centre, New Delhi, Delhi 110002, India. Electronic address: chopra_drkk@yahoo.co.in.
authors.forename: K K
authors.initials: KK
authors.lastname: Chopra
mesh_terms: D000995:Antitubercular Agents / Q000627:therapeutic use; D006801:Humans; D007194:India / Q000453:epidemiology; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000453:epidemiology* / Q000517:prevention & control
chemical_list: D000995:Antitubercular Agents
keywords: Clinical implication; Drug resistance; TB